Managing Massive Subretinal Hemorrhage Without Surgery - Takeaways - MDSpire

Managing Massive Subretinal Hemorrhage Without Surgery

Two patients with massive subretinal hemorrhage demonstrated sustained long-term stability following intravitreal anti-VEGF monotherapy.

  • By

  • Michael Y. Zhao, MD

  • Harry W. Flynn Jr., MD

  • July 1, 2026

  • 11 min

Share

  • 1

    Massive subretinal hemorrhage (mSRH) is defined as hemorrhage exceeding 3 to 4 disc diameters and is associated with poor visual prognosis.

  • 2

    Two patients with mSRH were successfully managed with intravitreal anti-VEGF monotherapy and showed long-term stability over 10 to 20 years.

  • 3

    The most common cause of mSRH is neovascular age-related macular degeneration, but other causes include retinal arterial macroaneurysms and polypoidal choroidal vasculopathy.

  • 4

    Anti-VEGF therapy has shown good efficacy and safety in treating mSRH, with studies indicating better early visual recovery compared to other treatment strategies.

  • 5

    Prompt treatment of mSRH is critical to prevent irreversible photoreceptor damage and improve visual outcomes.

Original Source(s)

Managing Massive Subretinal Hemorrhage Without Surgery

  • by Michael Y. Zhao, MD, Harry W. Flynn Jr., MD

  • July 1, 2026

Related Content

Trabeculotomy outcomes in paediatric patients with steroid-induced ocular hypertension or glaucoma: a case series and literature review

New Immune Target in Dry Eye

Investigators say rexinoid therapy may represent a new class of dry eye treatment focused on regenerative immune signaling

  • June 30, 2026

  • 3 min
Surgical Roundtable Case 3: Fixing a Tilted Secondary IOL

Christina Weng, MD, MBA, presents a case of secondary IOL tilt correction, highlighting a novel 5-point scaffold technique for lens stabilization, and a panel of expert vitreoretinal surgeons discusses rescue strategies, IOL exchange vs preservation, and pearls for managing postoperative lens tilt.